Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;185(1):1-12.
doi: 10.1007/s10549-020-05917-7. Epub 2020 Sep 13.

Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)

Abeer H Abdelhafez #  1 , Benjamin C Musall #  2 , Beatriz E Adrada  1 , KennethR Hess  3 , Jong Bum Son  2 , Ken-Pin Hwang  2 , Rosalind P Candelaria  1 , Lumarie Santiago  1 , Gary J Whitman  1 , Huong T Le-Petross  1 , Tanya W Moseley  1 , Elsa Arribas  1 , Deanna L Lane  1 , Marion E Scoggins  1 , Jessica W T Leung  1 , Hagar S Mahmoud  1 , Jason B White  4 , Elizabeth E Ravenberg  4 , Jennifer K Litton  4 , Vicente Valero  4 , Peng Wei  3 , Alastair M Thompson  5 , Stacy L Moulder  4 , Mark D Pagel  2   6 , Jingfei Ma  2 , Wei T Yang #  1 , Gaiane M Rauch #  7   8
Affiliations
Review

Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)

Abeer H Abdelhafez et al. Breast Cancer Res Treat. 2021 Jan.

Abstract

Purpose: To determine if tumor necrosis by pretreatment breast MRI and its quantitative imaging characteristics are associated with response to NAST in TNBC.

Methods: This retrospective study included 85 TNBC patients (mean age 51.8 ± 13 years) with MRI before NAST and definitive surgery during 2010-2018. Each MRI included T2-weighted, diffusion-weighted (DWI), and dynamic contrast-enhanced (DCE) imaging. For each index carcinoma, total tumor volume including necrosis (TTV), excluding necrosis (TV), and the necrosis-only volume (NV) were segmented on early-phase DCE subtractions and DWI images. NV and %NV were calculated. Percent enhancement on early and late phases of DCE and apparent diffusion coefficient were extracted from TTV, TV, and NV. Association between necrosis with pathological complete response (pCR) was assessed using odds ratio (OR). Multivariable analysis was used to evaluate the prognostic value of necrosis with T stage and nodal status at staging. Mann-Whitney U tests and area under the curve (AUC) were used to assess performance of imaging metrics for discriminating pCR vs non-pCR.

Results: Of 39 patients (46%) with necrosis, 17 had pCR and 22 did not. Necrosis was not associated with pCR (OR, 0.995; 95% confidence interval [CI] 0.4-2.3) and was not an independent prognostic factor when combined with T stage and nodal status at staging (P = 0.46). None of the imaging metrics differed significantly between pCR and non-pCR in patients with necrosis (AUC < 0.6 and P > 0.40).

Conclusion: No significant association was found between necrosis by pretreatment MRI or the quantitative imaging characteristics of tumor necrosis and response to NAST in TNBC.

Keywords: Diffusion-weighted MRI; Multiparametric MRI; Necrosis; Neoadjuvant therapy; Triple-negative breast cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Inclusion criteria and assignment of analysis for each group. ADC apparent diffusion coefficient, DCE dynamic contrast-enhanced imaging, DWI diffusion-weighted imaging, NAST neoadjuvant systemic therapy, NV necrosis-only volume, PE percent enhancement, T2WI T2-weighted imaging, TNBC triple-negative breast cancer, TTV total tumor volume including necrosis, TV tumor volume without necrosis
Fig. 2
Fig. 2
Necrosis in a 35-year-old woman with TNBC of the left breast. a Axial fat-suppressed early-phase dynamic contrast-enhanced image shows central non-enhancing area representing necrosis (arrow). b Axial fat-suppressed T2-weighted image shows necrosis as central area of high signal intensity (arrow). c Axial apparent diffusion coefficient map shows shine-through corresponding to central area of necrosis (arrow) seen on dynamic contrast-enhanced and T2-weighted imaging
Fig. 3
Fig. 3
Segmentation technique in a 60-year-old woman with TNBC of the right breast. Axial dynamic contrast-enhanced early-phase fat-suppressed images with whole tumor (a), tumor without necrosis (b), and necrosis-only (c) segmentations, as well as corresponding apparent diffusion coefficient maps (d, e, f)
Fig. 4
Fig. 4
Necrotic index carcinoma with a pathological complete response after neoadjuvant systemic therapy in a 46-year-old woman with TNBC of the right breast. The volume of necrotic material was 10 cm3, and the percent of the total tumor volume occupied by necrosis was 17%. a Axial fat-suppressed early-phase dynamic contrast-enhanced image shows central non-enhancing area representing necrosis (arrow). b Axial fat-suppressed T2-weighted image shows necrosis as central area of high signal intensity (arrow). c Axial apparent diffusion coefficient map shows shine-through corresponding to the central area of necrosis (arrow)
Fig. 5
Fig. 5
Necrotic index carcinoma with pathological non-complete response after neoadjuvant systemic therapy in a 30-year-old woman with TNBC of the left breast. The volume of necrotic material was 4 cm3, and the percent of the total tumor volume occupied by necrosis was 17%. a Axial fat-suppressed early-phase dynamic contrast-enhanced image shows central non-enhancing area representing necrosis (arrow). b Axial fat-suppressed T2-weighted image shows necrosis as a central area of high signal intensity (arrow). c Axial apparent diffusion coefficient map shows shine-through corresponding to central area of necrosis (arrow)
Fig. 6
Fig. 6
Clustering of necrosis volume or NVDCE (a) and necrosis-only volume as a percent of total tumor volume or %NVDCE (b), by dynamic contrast-enhanced MRI associated with response to neoadjuvant systemic therapy. There is no difference between TNBC patients with and without pathologic complete response (pCR)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bao C, Lu Y, Chen J, Chen D, Lou W, Ding B, Xu L, Fan W (2019) Exploring specific prognostic biomarkers in triple-negative breast cancer. Cell Death Dis 10(11):807. - PMC - PubMed
    1. Bae MS, Shin SU, Ryu HS, Han W, Im SA, Park IA, Noh DY, Moon WK (2016) Pretreatment mr imaging features of triple-negative breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival. Radiology 281(2):392–400 - PubMed
    1. Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS (2010) Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two international breast cancer study group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 121(1):211–218 - PMC - PubMed
    1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (er)-negative, progesterone receptor (pr)-negative, and her2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109(9):1721–1728 - PubMed
    1. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC (2011) The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 7(10):1223–1235 - PubMed